Monopar Therapeutics (NASDAQ:MNPR) Stock Falls 5.3% Following Insider Selling

Posted by Brenda Bartman on Sep 29th, 2026

Monopar Therapeutics Inc. (NASDAQ:MNPR – Get Free Report) shares were down 5.3% during trading on Tuesday following insider selling activity. The stock traded as low as $79.54 and last traded at $79.2650. Approximately 102,103 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 211,707 shares. The stock had previously closed at $83.72.

Specifically, CEO Chandler Robinson sold 29,056 shares of Monopar Therapeutics stock in a transaction dated Thursday, September 24th. The stock was sold at an average price of $88.00, for a total value of $2,556,928.00. Following the completion of the transaction, the chief executive officer owned 99,267 shares of the company’s stock, valued at $8,735,496. The trade was a 22.64% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. BTIG Research increased their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. HC Wainwright raised their target price on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Morgan Stanley reaffirmed an “overweight” rating and set a $130.00 price target on shares of Monopar Therapeutics in a report on Monday, August 17th. Wall Street Zen upgraded Monopar Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Friday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $121.36.

Get Our Latest Stock Analysis on Monopar Therapeutics

Monopar Therapeutics Stock Down 5.3%

The company’s 50 day moving average price is $109.77 and its two-hundred day moving average price is $82.32. The firm has a market cap of $531.87 million, a PE ratio of -36.71 and a beta of 1.49.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.02. On average, analysts expect that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp acquired a new stake in Monopar Therapeutics in the second quarter valued at approximately $7,124,000. Bank of America Corp DE increased its holdings in shares of Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after purchasing an additional 53,336 shares during the period. ADAR1 Capital Management LLC raised its position in Monopar Therapeutics by 13.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after buying an additional 30,370 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new position in shares of Monopar Therapeutics during the first quarter worth $250,000. Finally, Siren L.L.C. lifted its position in Monopar Therapeutics by 27.2% during the first quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after purchasing an additional 57,820 shares during the period. Hedge funds and other institutional investors own 1.83% of the company’s stock.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company’s programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar’s lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.